The global high flow nasal cannula market size was valued at USD 7.98 billion in 2025 and is projected to grow from USD 8.72 billion in 2026 to USD 17.66 billion by 2034, registering a CAGR of 9.23% during the forecast period (2026-2034). North America dominated the high flow nasal cannula market with a share of 37.63% in 2025.
High flow nasal cannula is a non-invasive respiratory support technique that delivers heated and humidified medical gas, consisting of air and supplemental oxygen that meet or exceed the patient's inspiratory flow demand. These devices are tracked under HSN Code 9018 (instruments and appliances used in medical and surgical sciences) and SIC Code 3841 (surgical and medical instruments and apparatus).
The high-flow nasal cannula market demand is driven by the prevalence of respiratory disorders, the need for non-invasive respiratory support, and the use of oxygen therapy in critical care settings. Medical device manufacturers are developing systems with improved humidification, precise oxygen delivery, and enhanced patient comfort, contributing to high flow nasal cannula market growth.
Download a Free Sample To learn more about this report,
Integration of Heated Humidification Systems for Improved Respiratory Support
The high flow nasal cannula market analysis shows a focus on integrated systems that deliver warmed and humidified respiratory gases at controlled flow rates. Heated humidification helps reduce airway dryness and supports patient comfort during extended respiratory therapy. These systems are used in hospital settings for patients who require noninvasive oxygen support.
Development of High Flow Nasal Cannula Systems for Pediatric and Neonatal Care
Manufacturers are refining high flow nasal cannula systems with smaller nasal interfaces, lower flow settings, and circuit designs suited to infants and children. These configurations help clinicians tailor respiratory support to patient size and clinical needs. Specialized pediatric and neonatal systems expand the use of high flow therapy beyond adult respiratory care.
Supply chain disruptions are expected to have a high impact on the high flow nasal cannula market share due to its direct exposure to shortages of medical-grade plastics, oxygen delivery tubing, and humidification chambers. A capacity-constrained recovery is likely, as specialized component manufacturing, device assembly, and quality testing can limit production. Supply chain constraints could reduce the projected growth rate from 9.23% to 7.73%, a decline of 1.50 percentage points. As supply conditions normalize, the high flow nasal cannula market growth is expected to gradually return to 9.23%.
The high flow nasal cannula market forecasts investment in respiratory support devices, heated humidification systems, and technologies that improve oxygen delivery for patients with breathing difficulties. In July 2026, Beyond Air announced a private placement offering expected to generate up to USD 30.1 million, including USD 10.2 million upfront and additional proceeds dependent on warrant exercises. The financing supports the planned commercial launch of its LungFit PH system, a nitric oxide delivery device for respiratory care.
Demand for Respiratory Support During Severe Pneumonia Treatment and Adoption of Humidified Oxygen Delivery Systems Drives Market
Severe pneumonia can cause low blood oxygen levels and breathing difficulties, creating a need for effective respiratory support. High flow nasal cannula devices deliver controlled oxygen at high flow rates, helping support patients with acute respiratory failure in appropriate clinical settings. The need for timely oxygen therapy in emergency departments and intensive care units is supporting demand for these devices.
Healthcare providers are adopting heated and humidified oxygen delivery systems to improve patient comfort during respiratory treatment. These systems help maintain moisture and temperature in the delivered gas, reducing dryness and irritation associated with high-flow oxygen therapy. Their ability to support comfortable, sustained oxygen delivery is encouraging adoption across hospitals and critical care facilities.
Patient Intolerance and Equipment Dependence Restrains Market Expansion
Some patients may experience nasal discomfort, dryness, irritation, or difficulty tolerating high-flow oxygen therapy over extended periods. These issues can reduce patient acceptance and require adjustments to gas temperature, humidity, or flow settings, which may limit the suitability of the therapy for certain individuals.
High flow nasal cannula systems require a reliable oxygen source, power supply, and suitable humidification equipment for proper operation. These requirements can raise setup and maintenance costs and restrict use in healthcare facilities with limited infrastructure, particularly in resource-constrained settings.
High Flow Nasal Cannula Systems for Interfacility Patient Transport and Humidification Monitoring Create Opportunities for Market Players
Interfacility patient transport offers a specialized opportunity for high-flow nasal cannula manufacturers. Patients who require respiratory support may need transfer between hospitals or from emergency departments to intensive care units. Manufacturers can develop compact systems with battery backup and secure oxygen connections for use during supervised patient transport.
Humidification monitoring offers another opportunity for device manufacturers to improve high-flow respiratory support. These systems deliver heated, humidified gas, so reliable control of temperature and moisture is important for patient comfort and therapy performance. Manufacturers can develop sensors and alerts that help clinicians identify deviations in humidifier performance and maintain suitable delivery conditions.
Oxygen blenders accounted for the largest share of 27.5% in 2025 due to their role in delivering controlled oxygen concentrations during respiratory support.
Active humidifiers are projected to register a CAGR of 9.8% during the forecast period, driven by the demand for heated and humidified respiratory gases to improve patient comfort.
Request Customizationto receive a tailored report.
Acute respiratory failure held a leading position with a share of 32.5% in 2025, supported by the demand for effective respiratory support among patients experiencing severe breathing difficulties. Advances in respiratory care continue to improve treatment options for patients.
Post-extubation respiratory support is expected to grow at a CAGR of 10.5% during the forecast period, fueled by the increasing use of high-flow oxygen therapy following the removal of mechanical ventilation.
In 2025, adults accounted for a dominant share of 42.8%, reflecting the widespread need for respiratory support among patients with acute and chronic breathing conditions. The high burden of respiratory illnesses in this population supports demand for high-flow oxygen therapy devices.
The neonatal and pediatric segment is anticipated to record a CAGR of 10.4% during the forecast period, propelled by the demand for specialized respiratory care for newborns and children.
Hospitals and intensive care units accounted for the largest share of 57.5% in 2025 due to the extensive use of high-flow oxygen therapy in emergency care, intensive care, and inpatient respiratory treatment.
Homecare is projected to register a CAGR of 11.6% during the forecast period, driven by the demand for home-based respiratory support and the growing preference for care outside hospital settings.
Speak to an Analystto discuss market opportunities.
The North America high flow nasal cannula market market accounted for a dominant share of 37.63% in 2025.
FDA classifies high-flow humidified oxygen delivery devices, including systems that use high-flow nasal cannulas, as Class II medical devices under 21 CFR 868.5454, with a 510(k) premarket notification pathway. This framework supports the commercial development of high-flow oxygen systems and creates demand for compatible humidifiers, oxygen-blending units, heated tubing and nasal cannula consumables.
Health Canada’s guidance for machine learning-enabled medical devices supports the development and assessment of medical technologies that use artificial intelligence. These advances encourage smarter respiratory monitoring, support clinical decision-making, and improve the management of patients requiring oxygen therapy.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific high flow nasal cannula market is will expand to 11.42% CAGR, showcasing the fastest-growing regional growth.
Researchers at Okayama University Hospital are studying the use of a hydrogen gas generator with high flow nasal cannula therapy for patients with acute respiratory distress syndrome. Such research supports innovation in respiratory treatment and expands the clinical applications of high flow nasal cannula devices in Japan.
High flow nasal cannula market in China is supported by research into patient comfort and device performance. Researchers at Qilu Hospital of Shandong University assessed how cannula size and oxygen flow rate affect airway pressure and patient comfort during HFNC therapy. These findings can inform cannula design and device settings for more comfortable respiratory support.
Indian companies are developing indigenous medical devices. Postgraduate Institute of Medical Education and Research, Chandigarh, transferred its locally developed TrueOxy+ system technology to Clarity Medical Pvt. Ltd. The partnership aims to enable domestic manufacturing of affordable respiratory equipment for hospitals and critical care units.
Europe's high flow nasal cannula market is expected to experience a growth rate of 8.9% during the forecast period.
A clinical trial registered with the German Clinical Trials Register is assessing a system that automatically adjusts oxygen levels based on patient oxygen saturation. Such research highlights efforts to improve precision in high-flow respiratory support and advance next-generation equipment.
Clinical research into neonatal respiratory care is expanding the evidence base for high flow nasal cannula devices in the United Kingdom. The University of Nottingham examined the use of heated, humidified high-flow nasal cannula therapy across neonatal units. This strengthens the role of high flow nasal cannula systems in neonatal care and supports wider use of specialized respiratory devices in hospitals.
The Latin Amercia high flow nasal cannula market is anticipated to record a growth rate of 9.5% during the forecast period. The New Industry Brazil policy prioritizes local development of medical equipment and health technologies to strengthen the national healthcare supply chain. This initiative supports local innovation and can expand the availability of respiratory support equipment for hospitals. Mexican Social Security Institute (IMSS) issued a tender for essential adult and neonatal high-flow therapy supplies in Tamaulipas, covering consumables used in high flow nasal cannula therapy.
The Middle East & Africa high flow nasal cannula market is projected to achieve a growth rate of 9.7% during the forecast period. A UAE healthcare tender listed i-Flo high-flow nasal cannulas in small, medium and large sizes, alongside respiratory circuits and non-invasive ventilation supplies, supporting suppliers of high flow nasal cannulas. South Africa’s high flow nasal cannula market benefits from clinical research into non-invasive respiratory support. Researchers at Groote Schuur Hospital in Cape Town studied high flow nasal oxygen as an initial treatment for patients with severe related respiratory failure.
The high flow nasal cannula market competitive landscape is competitive, with established respiratory care device manufacturers, medical technology companies, and oxygen therapy solution providers. Key players such as Fisher & Paykel Healthcare, Teleflex, ResMed, Vapotherm, and Masimo are estimated to account for 60% of the global high-flow nasal cannula market share.
Established players compete mainly through oxygen delivery performance, patient comfort, device reliability, humidification technology, and clinical effectiveness. Emerging regional players focus on affordable respiratory support systems, specialized oxygen delivery solutions, and products tailored to hospitals, intensive care units, and emergency care settings.
April 2026: Vapotherm received United States Food and Drug Administration clearance for its All Patient Circuit.
January 2026: Postgraduate Institute of Medical Education and Research transferred its indigenously developed TrueOxy high flow nasal cannula technology to Clarity Medical.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Experts
The Straits Research Team is a group of experienced researchers, analysts, and industry professionals dedicated to delivering reliable, insightful, and well-structured market intelligence. With expertise across multiple sectors and domains, the team combines extensive research, data analysis, and industry knowledge to provide a clear understanding of evolving markets and business environments.
The team focuses on identifying key market trends, emerging opportunities, technological developments, competitive landscapes, and changing industry dynamics. Through a thoughtful and research-driven approach, it aims to provide valuable insights that help businesses, investors, and decision-makers better understand their industries and make informed strategic decisions.
Adult Pediatric Hemoconcentrators Market Size, Opportunities, 2034
Handheld Backscatter X-Ray Devices Market Size, Share, Growth, 2034
Arterial Cannula Market Size, Forecast, Demand, Opportunities, 2034
Ultrasound Devices Market Size, Share, Growth, Analysis, 2034
Catheter Directed Thrombolysis Market Size, Forecast, Demand, Opportunities, 2034
Breast Biopsy Device Market Size, Forecast, Opportunities, 2034
We are featured on:
sales@straitsresearch.com